APO Research
Talk to an analyst

APO RESEARCH · REPORT

SGLT-2 Inhibitors for Type 2 Diabetes Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Outlook and Growth Opportunities 2026

30 December 2025192 pages

Choose your research edition.

Industry ResearchSGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the SGLT-2 Inhibitors for Type 2 Diabetes Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the SGLT-2 Inhibitors for Type 2 Diabetes Treatment market include Astellas, Boehringer Ingelheim, Chugai Pharmaceutical, Taisho Pharmaceutical, AstraZeneca, Jiangsu Hengrui Medicine, Merck, Johnson & Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents SGLT-2 Inhibitors for Type 2 Diabetes Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the SGLT-2 Inhibitors for Type 2 Diabetes Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Company

Astellas

Boehringer Ingelheim

Chugai Pharmaceutical

Taisho Pharmaceutical

AstraZeneca

Jiangsu Hengrui Medicine

Merck

Johnson & Johnson

Sanofi

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Canagliflozin

Empagliflozin

Dapagliflozin

Others

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Application

E-commerce and Internet Medical Care

Offline Retail Pharmacy

Hospitals and Clinics

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions SGLT-2 Inhibitors for Type 2 Diabetes Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify SGLT-2 Inhibitors for Type 2 Diabetes Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze SGLT-2 Inhibitors for Type 2 Diabetes Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SGLT-2 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SGLT-2 Inhibitors for Type 2 Diabetes Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment industry.

Chapter 3: Detailed analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of SGLT-2 Inhibitors for Type 2 Diabetes Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of SGLT-2 Inhibitors for Type 2 Diabetes Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends Table 2. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers Table 3. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges Table 4. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints Table 5. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Company (2021-2026) Table 7. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Company (M Pcs) & (2021-2026) Table 8. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Company (2021-2026) Table 9. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Pcs) of Company (2021-2026) Table 10. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Company Manufacturing Base & Headquarters Table 12. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company, Product Type & Application Table 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Canagliflozin Table 18. Significant Companies of Empagliflozin Table 19. Significant Companies of Dapagliflozin Table 20. Significant Companies of Others Table 21. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (M Pcs) Table 22. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2021-2026) & (M Pcs) Table 23. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2027-2032) & (M Pcs) Table 24. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Type (2021-2026) Table 25. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Type (2027-2032) Table 26. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type (2021-2026) Table 30. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type (2027-2032) Table 31. Significant Companies of E-commerce and Internet Medical Care Table 32. Significant Companies of Offline Retail Pharmacy Table 33. Significant Companies of Hospitals and Clinics Table 34. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (M Pcs) Table 35. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2021-2026) & (M Pcs) Table 36. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2027-2032) & (M Pcs) Table 37. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Application (2021-2026) Table 38. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Application (2027-2032) Table 39. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application (2021-2026) Table 43. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application (2027-2032) Table 44. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Table 45. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (M Pcs) Table 46. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2021-2026) Table 47. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032) & (M Pcs) Table 48. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2027-2032) Table 49. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Region (2021-2026) Table 52. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Region (2027-2032) Table 54. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Average Price (US$/K Pcs) by Region (2021-2026) Table 55. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Average Price (US$/K Pcs) by Region (2027-2032) Table 56. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 57. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 59. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 60. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 61. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2027-2032) Table 62. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Market Share by Country (2021-2026) Table 64. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Market Share by Country (2027-2032) Table 66. Astellas Company Information Table 67. Astellas Business Overview Table 68. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 69. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 70. Astellas Recent Development Table 71. Boehringer Ingelheim Company Information Table 72. Boehringer Ingelheim Business Overview Table 73. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 74. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 75. Boehringer Ingelheim Recent Development Table 76. Chugai Pharmaceutical Company Information Table 77. Chugai Pharmaceutical Business Overview Table 78. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 79. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 80. Chugai Pharmaceutical Recent Development Table 81. Taisho Pharmaceutical Company Information Table 82. Taisho Pharmaceutical Business Overview Table 83. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 84. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 85. Taisho Pharmaceutical Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 89. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 90. AstraZeneca Recent Development Table 91. Jiangsu Hengrui Medicine Company Information Table 92. Jiangsu Hengrui Medicine Business Overview Table 93. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 94. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 95. Jiangsu Hengrui Medicine Recent Development Table 96. Merck Company Information Table 97. Merck Business Overview Table 98. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 99. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 100. Merck Recent Development Table 101. Johnson & Johnson Company Information Table 102. Johnson & Johnson Business Overview Table 103. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 104. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 105. Johnson & Johnson Recent Development Table 106. Sanofi Company Information Table 107. Sanofi Business Overview Table 108. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 109. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 110. Sanofi Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors List Table 114. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Image Figure 2. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032) & (M Pcs) Figure 5. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Average Price (US$/K Pcs) & (2021-2032) Figure 6. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Canagliflozin Image Figure 10. Empagliflozin Image Figure 11. Dapagliflozin Image Figure 12. Others Image Figure 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Type (2021-2032) Figure 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type (2021-2032) Figure 19. E-commerce and Internet Medical Care Image Figure 20. Offline Retail Pharmacy Image Figure 21. Hospitals and Clinics Image Figure 22. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 23. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Application (2021-2032) Figure 25. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application (2021-2032) Figure 28. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Figure 29. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain Figure 127. Manufacturing Cost Structure Figure 128. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Canagliflozin
  • Empagliflozin
  • Dapagliflozin
  • Others
Applications
  • E-commerce and Internet Medical Care
  • Offline Retail Pharmacy
  • Hospitals and Clinics
Companies covered
  • Astellas
  • Boehringer Ingelheim
  • Chugai Pharmaceutical
  • Taisho Pharmaceutical
  • AstraZeneca
  • Jiangsu Hengrui Medicine
  • Merck
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  4. 1.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Dynamics
  1. 2.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends
  2. 2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
  3. 2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
  4. 2.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Company
  1. 3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Revenue Ranking in 2025
  2. 3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Company (2021-2026)
  3. 3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price by Company (2021-2026)
  5. 3.5 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Ranking (2024-2026)
  6. 3.6 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Product Type and Application
  8. 3.8 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Type
  1. 4.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Type Introduction
  2. 4.1.1 Canagliflozin
  3. 4.1.2 Empagliflozin
  4. 4.1.3 Dapagliflozin
  5. 4.1.4 Others
  6. 4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type
  7. 4.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Type (2021-2032)
  9. 4.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Type (2021-2032)
  10. 4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type
  11. 4.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Type (2021-2032)
  13. 4.3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type (2021-2032)
5 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Application
  1. 5.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Application Introduction
  2. 5.1.1 E-commerce and Internet Medical Care
  3. 5.1.2 Offline Retail Pharmacy
  4. 5.1.3 Hospitals and Clinics
  5. 5.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application
  6. 5.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application
  10. 5.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application (2021-2032)
6 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Regional Sales and Value Analysis
  1. 6.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032)
  5. 6.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  12. 6.6.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  21. 6.9.2 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Country, 2025 VS 2032
7 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Country-level Sales and Value Analysis
  1. 7.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032)
  6. 7.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas
  2. 8.1.1 Astellas Company Information
  3. 8.1.2 Astellas Business Overview
  4. 8.1.3 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  6. 8.1.5 Astellas Recent Developments
  7. 8.2 Boehringer Ingelheim
  8. 8.2.1 Boehringer Ingelheim Company Information
  9. 8.2.2 Boehringer Ingelheim Business Overview
  10. 8.2.3 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  12. 8.2.5 Boehringer Ingelheim Recent Developments
  13. 8.3 Chugai Pharmaceutical
  14. 8.3.1 Chugai Pharmaceutical Company Information
  15. 8.3.2 Chugai Pharmaceutical Business Overview
  16. 8.3.3 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  18. 8.3.5 Chugai Pharmaceutical Recent Developments
  19. 8.4 Taisho Pharmaceutical
  20. 8.4.1 Taisho Pharmaceutical Company Information
  21. 8.4.2 Taisho Pharmaceutical Business Overview
  22. 8.4.3 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  24. 8.4.5 Taisho Pharmaceutical Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Jiangsu Hengrui Medicine
  32. 8.6.1 Jiangsu Hengrui Medicine Company Information
  33. 8.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 8.6.3 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Johnson & Johnson
  44. 8.8.1 Johnson & Johnson Company Information
  45. 8.8.2 Johnson & Johnson Business Overview
  46. 8.8.3 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  48. 8.8.5 Johnson & Johnson Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
  2. 9.1.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Mode & Process
  6. 9.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors
  9. 9.2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst